Latest posts by Makeba Giles (see all)
- Is Using an Online Drugstore Really a Better Choice? - January 12, 2018
- Improve Your Health by Using These 3 Simple Hacks to Get a Better Sleep - January 11, 2018
- Pack Your Bags: A New Series of Luxury China Tours is Now Available - December 20, 2017
There is a desperate need for effective treatments in Alzheimer’s. By the year 2050, it is estimated that 115 million people worldwide will have Alzheimer’s disease. Currently, five million Americans are living with Alzheimer’s, including half a million under the age of 65.
Researchers are now shining a spotlight on the connection between sleep and slowing the effects of Alzheimer’s.
The disease is a growing crisis in the United States and research has identified a correlation between Alzheimer’s disease and poor sleep. Sleep disturbances are seen in 63% of patients with subtle dementia and research shows that poor sleep is directly related to cognitive decline.
A new investigative Alzheimer’s trial, ReCOGNITION, is a Phase 2 clinical trial for which participants are needed. The ReCOGNITION study is being conducted at approximately 75 research centers across the United States.
Researchers are seeking patients aged 60 to 85 who have been diagnosed with mild dementia due to Alzheimer’s. Participants will be seen by a doctor and will receive all study-related care and medication at no cost.
Dr. Steven D. Targum joined me to share more about the latest Alzheimer’s research. He also shared details about the study and options available.
Take a look at our chat below.
For more information visit: recognitionstudy.com
Meet Our Guest:
Dr. Targum consults widely to the pharmaceutical industry in the areas of psychiatric disorders, clinical trial methodologies, protocol design, study surveillance strategies, study analysis, and the progression of new drug candidates from concept to approval to launch.
Dr. Targum is currently the Scientific Director at Bracket Global where he is focused on optimizing signal detection for clinical trials across the CNS spectrum. Dr. Targum has been Chief Medical Officer at Brain Cells Inc., Methylation Sciences Inc., and Functional Neuromodulation Inc. He is currently the Chief Medical Officer at Resilience Therapeutics investigating post-traumatic stress disorder and Chief Medical Advisor at Neurim Pharmaceuticals where he assists with the execution of a clinical trial for Alzheimer’s disease.